[Skip to Navigation]
November 1967

The Skin and Antitumor Drugs: A Special Lecture in Honor of Dr. Charles C. Dennie

Author Affiliations

Bethesda, Md

From the National Cancer Institute, Bethesda, Md.

Arch Dermatol. 1967;96(5):560-564. doi:10.1001/archderm.1967.01610050082014

THE CHEMOTHERAPY of cancer has developed rapidly in the last few years, and I should like in this discussion to mention briefly some of the implications of this growing body of knowledge for dermatology and for the dermatologist. I shall first describe the effects of antitumor drugs on normal skin, on tumors of the skin, and upon diseases other than cancer, and then review some of the conceptual advances in cancer chemotherapy. I have omitted any discussion of the antitumor hormones.

A large number of patients in this country are receiving antitumor drugs and this number is increasing rapidly. Consultants will see an ever increasing number of patients receiving these agents and should be aware of their potentialities. An excellent summary for quick reference purposes appeared in a recent Medical Letter.1 The Table shows the antitumor drugs approved for commercial distribution, and those under investigational study likely to

Add or change institution